Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Small Cell Lung Carcinoma 52Neoplasms 8Melanoma 8Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Mesothelioma, Malignant 6Mesothelioma 6Colorectal Neoplasms 6Carcinoma 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Respiratory Tract Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Diseases 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Bronchogenic 3Bronchial Neoplasms 3Adenocarcinoma of Lung 3

Interventions

pembrolizumab 2toripalimab 1sintilimab 1pemigatinib 1osimertinib 1durvalumab 1Vinorelbine 1Platinum Compounds 1Nivolumab 1Ipilimumab 1Drug Therapy 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non Small Cell Lung Cancer × durvalumab × Thoracic × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡